Advertisement


Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

2024 ASCO Annual Meeting

Advertisement

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
TIO represents a groundbreaking first-in-class, small molecule where directed targets telomeres in cancer cells. Specifically those telomeres positive with over 80% of all cancers, and approximately 78-83% of all non-small cell and cancer types being third positive. This innovative approach is particularly significant. TIO operates for a dual mechanism of action. Firstly, it targets telomeres by incorporating itself into newly synthesized telomeres, leading to chromatin uncapping, the generation of DNA damage signals and rapid apoptosis of cancer cells. Secondly, it has an immunogenic effect that enhances the body's immune response against the tumor. In preclinical models sequential treatment with TIO and immune checkpoint inhibitors has demonstrated potent and durable anti-tumor activity, for instance, in non-small cell lung cancer, combining TIO with atezolizumab resulted in a 60% complete response rate with an anti-cancer [inaudible 00:01:08]. In colorectal cancer achieved 100% complete responses with similar promising results in small cell and cancer as well as in hepatocellolar carcinoma. Turning our attention to the TIO-101 trial, it's a phase two dose optimization study for adult patients with advanced or metastatic non-small cell lung cancer who progress or relapse after one to four prior treatments, including immuno and platinum chemotherapy. Using assignment to stage design, 79 patients were assigned to receive one of three doses of TIO. 360, 180 or 60 milligrams, followed by semi-primab every three weeks for up to a year. The combination of TIO and semi-primab has been well tolerated by this heavily pre-treated patients. We have observed significant activity in this difficult to treat group, including both resistant to checkpoint inhibitors and chemotherapy. Importantly, the presence of TIO in circulating tumor cells has shown on target effects. In November, 2023, the ongoing phase two study identified with 180 milligram dose of TIO is the optimal dose, demonstrating better safety and superior efficacy compared to other doses. Specifically, only 9.8% of patients receiving 180 milligram dose reported grade three adverse events related to treatment with no grade four or five adverse events. Per safety profile suggests that TIO could potentially offer a far better alternative to chemotherapy. In terms of efficacy in the third line setting, disease control rate reached 85% for TIO with semi-primab comparing to 25-35% typically observed with standard chemotherapy. We have also seen long-term responses. With five patients having survival follow up for over 12 months, three of them are still on treatment. The median survey will follow up in the third line is 9.1 months. Moreover, overall response rate in the third line with dose 180 milligrams of TIO was 38%, comparing to about 6% for other treatment possibilities. In conclusion, the safety and efficacy achievements of TIO are truly promising. We are confirming many of the assumptions [inaudible 00:03:18] observed in the pre-clinical studies, and we are looking forward to follow up our patients.

Related Videos

Breast Cancer

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).

Breast Cancer

Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study

Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; and DB07 on trastuzumab deruxtecan with or without palbociclib.

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Skin Cancer

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).

 

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Advertisement

Advertisement




Advertisement